BioSpace News Archive

Policy

Novartis’ CAR-T Treatment Kymriah Snags Second Approval in the U.K.

Four months after getting the green light in the U.K. for treatment of children with acute lymphoblastic leukemia (ALL), Novartis’ CAR-T treatment Kymriah, known as Tisagenlecleucel in the U.K., has gained approval for treatment of adults with diffuse large B-cell lymphoma (DLBCL).

February 1, 2019

·

3 min read

·

Alex Keown

BioForest

HHS Secretary Azar Floats Plan to Lower Prescription Drug Costs

The plan is aimed at providing new transparency to the prescription drug market and removing the veil of hidden rebates conducted between companies and pharmacy benefits managers.

February 1, 2019

·

3 min read

·

Alex Keown

Business

Q4 Biopharma Themes: Strong 2018, Weaker 2019 Earnings Projections, Concerns Over Drug Pricing

Many of the big biopharma companies reported fourth-quarter and year-end earnings this week. If there’s a theme among them, it seems lower earnings per share are forecast for the year.

February 1, 2019

·

5 min read

·

Mark Terry

Policy

A Deeper Look at Drug Shortages in the U.S.

Recently, in the U.S., there has been a shortage of an anti-anxiety drug, buspirone. The American Society of Health-System Pharmacists (ASHP) lists shortages, and as of Jan. 31, 2019, noted shortages of buspirone tablets manufactured by Accord Healthcare, Mylan and Teva Pharmaceutical.

February 1, 2019

·

4 min read

·

Mark Terry

Deals

Gossamer Bio Goes With Conventional IPO Pathway... Again

You have to give San Diego-based Gossamer Bio credit for the way it’s adapted its plans for an initial public offering (IPO) to deal with the government shutdown.

February 1, 2019

·

2 min read

·

Mark Terry

Drug Development

AVEO Oncology Delays NDA for Kidney Cancer Drug

Shares of AVEO Oncology plunged 45 percent Thursday trading after the Cambridge, Mass.-based company said it accepted the recommendation of the U.S. Food and Drug Administration to not seek regulatory approval of its kidney cancer drug, Tivozanib at this time.

February 1, 2019

·

2 min read

·

Alex Keown

Business

Takeda Reports Third Quarter FY2018 Results

Strong underlying growth year-to-date driven by business momentum and execution of the Global Opex Initiative; Underlying Core Earnings +32.3% with margin expansion of 530 basis points

February 1, 2019

·

12 min read

Aphria Introduces First Cannabis Strains to be Produced in Europe with Export to Danish Partner Schroll Medical

Aphria Inc. has completed its first transfer of plant cuttings from four of the Company’s cannabis strains to Denmark-based Schroll Medical, as part of the Company’s previously announced Strategic Partnership with Schroll.

February 1, 2019

·

4 min read

Business

Heroic U.S. Ebola Doctor Honored in NYC for Long-Time Medical Missionary Service in Liberia, West Africa

Prestigious $500,000 AMH Gerson L’Chaim Prize presented to SIM Missionary Dr. Rick Sacra will help extend and expand SIM’s healthcare ministry in impoverished Liberia

February 1, 2019

·

5 min read

Deals

Isofol Reports All Employees Participate in Newly Created Share Warrant Program

Isofol Medical AB,, today announced that all senior executives and employees participated in Isofol’s share warrant program “2018".

February 1, 2019

·

3 min read